The onset of Zepbound's effects can vary, but patients may begin to see improvements in their blood sugar levels and weight within a few weeks of starting treatment. Continuous use in conjunction with diet and exercise enhances its efficacy.

Yes, Zepbound is a prescription medication. You will need to consult a healthcare provider to determine if it's appropriate for your condition and to receive a prescription. Using our online consultation service will enable you to answer a short questionnaire that would be used by one of our clinical prescribers to determine your eligibility for the treatment and approve or decline and refund your order.

Zepbound is administered as a subcutaneous injection once a week. It can be injected into the abdomen, thigh, or upper arm, with the site of injection rotated each week to minimise the risk of skin irritation.

Zepbound should be stored in a refrigerator at 2°C to 8°C (36°F to 46°F). Do not freeze. Keep the pen in its original packaging to protect from light. Once in use, it may be kept at room temperature for 30 days.

Wegovy and Zepbound are both injectable medications used primarily for weight management in adults, but they differ in their active ingredients and mechanisms of action.

Wegovy:

Active Ingredient: Semaglutide.
Mechanism of Action: Wegovy functions as a GLP-1 receptor agonist, mimicking the action of the glucagon-like peptide-1 hormone which regulates appetite and calorie intake. It enhances feelings of fullness and reduces hunger, leading to a reduction in food intake.
Usage: Approved for chronic weight management in adults with obesity or overweight with at least one weight-related condition such as hypertension, type 2 diabetes, or dyslipidemia.

Zepbound:

Active Ingredient: Tirzepatide.
Mechanism of Action: Zepbound is unique in that it acts as both a GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptor agonist. This dual action not only helps in reducing appetite and food intake like GLP-1 agonists but also enhances insulin secretion in a glucose-dependent manner and possibly affects fat metabolism.
Usage: Initially approved for the treatment of type 2 diabetes, with promising results in significant weight reduction, leading to its approval for use in obesity management as well.

While both medications are part of a broader category of drugs used for metabolic management, the dual mechanism of Zepbound may offer broader metabolic effects compared to Wegovy. Both have shown effectiveness in weight loss and improvements in various metabolic parameters in clinical trials, but the choice between them may depend on individual health profiles, specific medical conditions, and healthcare provider recommendations.